CVRx's Exciting Participation at an Esteemed Healthcare Conference
CVRx, Inc. (NASDAQ: CVRX), a pioneering medical device firm, is set to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. This event, a notable gathering in the healthcare sector, will take place on a Wednesday in December, providing a platform for CVRx to showcase its advancements in neuromodulation for cardiovascular diseases.
What to Expect from the Fireside Chat
The fireside chat is slated for the afternoon, allowing industry stakeholders and investors to gain valuable insights about CVRx's strategies, product innovations, and future goals. Through this discussion, CVRx aims to highlight how its technology is shaping the landscape of cardiovascular treatments.
Understanding CVRx and Its Mission
Founded with a commitment to enhance the quality of life for heart failure patients, CVRx has developed the Barostim™ device. This groundbreaking technology is the first FDA-approved solution that utilizes neuromodulation to alleviate symptoms associated with heart failure. The device works by sending electrical pulses to baroreceptors in the carotid artery, aiming to restore the autonomic nervous system's balance.
Innovative Solutions for Heart Failure
Barostim™ has made significant strides since receiving its breakthrough designation from the FDA. It’s specifically designed to help patients who often struggle with the debilitating effects of heart failure. By targeting the nervous system, it offers a new avenue for symptom relief, particularly for those who haven’t responded adequately to traditional treatments.
Global Recognition of Barostim™ Technology
The FDA's endorsement of Barostim™ reflects its potential to impact patient care substantially. Additionally, it has achieved compliance with the EU's Medical Device Regulation and holds a CE Mark, allowing its use in the European Economic Area for both heart failure and resistant hypertension. This recognition underscores its reliability and efficacy in managing cardiovascular conditions.
Stay Updated on CVRx Developments
Those interested in following CVRx's progress can tune in to the live audio webcast of the fireside chat, available on the company's online investor relations page. This platform is an excellent resource for investors and stakeholders who wish to stay informed about the latest developments and strategic initiatives undertaken by CVRx.
Meet the CVRx Team
Investor communications are facilitated through a dedicated team, ensuring that questions and inquiries are promptly addressed. Mark Klausner and Mike Vallie from ICR Healthcare are available for insights and updates, while media groups can connect with Emily Meyers for further information.
Contact Information
For inquiries, investors can reach out via phone at 443-213-0501 or can send an email to ir@cvrx.com. Media requests should be directed to emeyers@cvrx.com or through the provided contact numbers.
Frequently Asked Questions
What is the Barostim™ technology?
Barostim™ is an FDA-approved medical device utilizing neuromodulation to alleviate heart failure symptoms by restoring balance to the autonomic nervous system.
When will CVRx participate in the Piper Sandler Conference?
The participation is scheduled for a Wednesday in December, providing a prime opportunity for stakeholders to engage with the management team.
How can I access the live webcast?
The live audio webcast will be available on CVRx's investor relations webpage, allowing everyone to tune in for important updates.
Who should I contact for investor inquiries?
Investors are encouraged to reach out to Mark Klausner or Mike Vallie at 443-213-0501 for any inquiries or information.
What are the company’s future goals?
CVRx aims to expand its product offerings and enhance patient outcomes through innovative medical device solutions for cardiovascular diseases.
